

# New methods and strategies for the stereocontrolled synthesis of polypropionate-derived natural products

Ian Paterson


University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, UK.

**Abstract:** By using the stereoregulated aldol reactions of chiral enol borinates with aldehydes, the synthesis of elaborate segments of polypropionate-derived natural products can be readily achieved. Stereocontrol may originate from the chiral influence of the boron reagent, the starting ketone (dependent on substitution pattern and enol borinate geometry), and the aldehyde, or from some combination of these (multiple asymmetric induction). Subsequent elaboration of the  $\beta$ -hydroxy ketone adducts can then be performed with a high level of overall diastereoselectivity. Examples of these reactions are given in the context of the synthesis of various polypropionate-derived natural products, including antibiotics (oleandomycin, rifamycin S), antitumour agents (swinholid A), enzyme inhibitors (ebelactone A), and marine polypropionates (denticulatin A and B).


## INTRODUCTION

The polyketide family of natural products represent a diverse array of structurally complex compounds, having a wide range of biological activity (typically antibiotic, antitumour, antiparasitic, or immunomodulatory action). Many of these are referred to as polypropionates, reflecting their common biosynthesis from propionate and to a lesser extent acetate units.

Scheme 1



## GENERAL ALDOL ANALYSIS FOR EXTENDED POLYPROPIONATES




As organic chemists strive to design and execute ever shorter and more efficient polypropionate syntheses, strategies using acyclic stereocontrol have become increasingly important [ref. 1]. Typically, this involves the aldol addition or allylation of an aldehyde by a suitable propionate equivalent. Excellent chiral propionate reagents have been developed by many research groups. However, their iterative application to polypropionate segments with many contiguous stereogenic centres, as occur in the secoacids of oleandomycin (1) or swinholid A (2), may not be ideal. In particular, such linear biomimetic approaches usually require several synthetic steps to give the new aldehyde for the next propionate addition.

The direct synthesis of extended polypropionate segments like 3 and 4 by aldol reactions of ethyl ketones 5–7 with aldehydes is outlined in Scheme 1. With unsaturated aldehydes, e.g. methacrolein, elaboration of the alkene groups in 4 allows further stereocentres to be introduced. Provided high levels of regio- and stereocontrol are possible, this strategy offers a simple and attractive alternative to conventional propionate extension on aldehydes. Both substrate- and reagent-based methods for achieving this control are discussed in this article.

## THE BORON ALDOL REACTION FOR ETHYL KETONES

The aldol reaction of boron enolates [ref. 2] is especially useful in this context. The enol borinate is first generated from the ketone and a boron reagent,  $L_2BX$  ( $X = Cl, OTf$ ), then directly reacted with the required aldehyde as shown in **Scheme 2**. For sterically demanding  $L$  groups on boron, the relationship  $Z$  enolate  $\rightarrow$  syn aldol and  $E$  enolate  $\rightarrow$  anti aldol holds. This ensues from reaction through a chair transition structure with  $R^2$  in the aldehyde equatorially arranged. Chiral substituents on the boron atom or the ketone give chiral  $Z$  and  $E$  enol borinates, leading to the diastereomeric chair transition structures ( $TS-I, II, \dots$ ) shown. Using an aldol force field based on MM2, computer modelling of these competing transition structures reproduces experimental aldehyde *re/si* selectivities and isomer ratios (syn-I/II, anti-I/II) for a range of  $L, R^1$  and  $R^2$  [ref. 3].

**Scheme 2** ALDOL TRANSITION STRUCTURES FOR  $R^1$  AND/OR  $L$  CHIRAL




For general utility in polypropionate synthesis, the various stereo- and regiochemical criteria listed below must be satisfied. Ideally, the chiral boron reagents used should also be easily prepared without recourse to resolution.

- Enolisation regioselectivity with unsymmetrical ethyl ketones,  $R^1 \neq Et$ ?
- Enolisation  $E/Z$  stereoselectivity?
- Enol borinate *re/si* selectivity in aldol addition to aldehydes (achiral and chiral)?
- Extension to methyl ketones?

Three distinct types of ethyl ketone aldol reaction emerge from the general analysis in **Scheme 1**. These are considered in turn.

#### ALDOL-1: Enantioselective aldol reactions of ethyl ketones using chiral boron reagents (5 $\rightarrow$ 6 in **Scheme 1**)

For reagent control in the aldol reactions of ethyl and methyl ketones with aldehydes, we use the chiral boron reagents **9**, **10**, and **11**, or their enantiomers. These are readily available in two steps from the appropriate enantiomer of  $\alpha$ -pinene or menthone (*i.e.* no resolution step is required).



**Syn aldol reactions.** Ethyl ketone aldol reactions with reagent **9** and  $^iPr_2NEt$  as the base proceed via the  $Z$  enol diisopinocampheylborinates **12**,  $L = lpc$  (**Scheme 3**) [ref. 4]. With most unsymmetrical ketones, highly regioselective enolisation occurs towards the ethyl side. For this and other boron triflate reactions,  $Z$  enolates are presumably formed by the hindered amine selecting between the two available  $C=O \cdot BL_2OTf$  complexes, leading to kinetic deprotonation trans to the boron group as shown [ref. 5]. These chiral enol borinates then add to aldehydes with high diastereoselectivity and useful levels of *si/re* discrimination (5:1–27:1 for syn-I/syn-II). For the  $(-)$ -lpc<sub>2</sub>BOTf reaction, MM2 calculations [ref. 3] indicate that  $TS-I$  is preferred over  $TS-II$ , where the lpc ligands are conformationally locked (**Fig. 1**).

**Anti aldol reactions.** These require a hindered dialkylboron chloride reagent and Et<sub>3</sub>N as the base for enolisation stereocontrol, e.g. reagent **10** gives predominantly the *E* enol borinate **13**, L = ipc. Related results are known from Brown's work using dicyclohexylboron chloride [ref. 6]. We believe that the unhindered amine selects between the two available C=O·BL<sub>2</sub>Cl complexes, leading now to kinetic deprotonation *cis* to the boron group as shown. The conformational preferences and reactivity of these intermediate Lewis acid-ketone complexes are being probed by *ab initio* MO calculations [ref. 7]. Unfortunately, the ipc ligands are ineffective for asymmetric anti aldol reactions. A collaboration with Cesare Gennari's group at Milan has recently led to the computer-aided design of the new reagent **11** [ref. 8]. Molecular mechanics calculations (MM2) indicate that the aldol *TS-IV* is preferred over *TS-III* in **Scheme 2**, suggesting synthetically useful *re/si* selectivity. In fact, experiments show that reagent **11** gives anti aldols with good levels of enantioselectivity (4:1–16:1 for anti-II/anti-I). Improved reagents are now being designed and prepared using such rational transition state modelling.

Scheme 3

**SYN ALDOL REACTION ← ETHYL KETONES → ANTI ALDOL REACTION**






Fig. 1



Scheme 4

**METHYL KETONE ALDOL REACTION**




**Methyl ketones.** The combination of chloride reagents **10** or **11** with Et<sub>3</sub>N as base is particularly effective for enolising methyl ketones to give **14** (**Scheme 4**). Even methyl ethyl ketone only enolises towards the methyl side. Reagent **11** gives aldol adducts **15** with 54–76% ee, suggesting chair *TS-IV* in **Scheme 2** is operating for both this and the *E* enolate reaction [ref. 8]. The ipc reagent **10** gives similar results [ref. 4], except that the hydroxyl configuration in **15** is reversed compared to **12** → *syn*-I. The aldehyde is now apparently reacting on its *re*-face with **14**, L = ipc, through a twist-boat transition structure. While the level of asymmetric induction is only modest, it may be useful for diastereoselective aldol additions using chiral methyl ketones and/or chiral aldehydes (double and triple asymmetric induction).

**ALDOL-2: Diastereoselective aldol reactions of α-chiral ethyl ketones (7→8 in Scheme 1)**

We have introduced (*R*)- and (*S*)-**16** as versatile dipropionate equivalents for the synthesis of polypropionate natural products (**Scheme 5**). These α-chiral ethyl ketones are prepared in ≥97% ee in three steps from commercial (*R*)-(-) and (*S*)-(+)-methyl 2-methyl-3-hydroxypropionate, respectively [ref. 9]. Three out of four of the diastereomeric aldol adducts **17** can be obtained selectively for any aldehyde (**Scheme 6**). Using appropriate reagents, the subsequent ketone reduction gives either the *syn* or *anti* 1,3-diol **18**, directly incorporating the six carbon atoms and stereogenic centre from **16**. For R = isopropenyl (*i.e.* methacrolein as the aldehyde), stereoregulated alkene hydration gives a general entry into stereopentads, **18** → **19** [ref. 10]. All thirty-two stereoisomers of **19** can be accessed in this way. Altogether, this provides a systematic approach to

specific stereopentad sequences for the synthesis of polypropionate-derived natural products of known structure, as well as assisting the assignment of stereochemistry in unknown structures and for the synthesis of unnatural analogues.

Scheme 5



***E* enolate.** Efficient substrate control is possible in the anti aldol reaction of (*S*)-16 via the *E* enol dicyclohexylborinate **20** to give the anti-anti adduct **21** in  $\geq 95\%$  ds by re-face attack on the aldehyde [ref. 9b]. This reaction is remarkable, as no chiral auxiliary or reagent is needed and the benzyloxymethyl substituent appears to give optimum selectivity. We believe that the reaction proceeds preferentially through *TS-V*, which minimises A(1,3) allylic strain and has a contra-steric preference for the benzyloxymethyl oxygen to be directed in towards the aldehyde. This effect must have an electronic origin, which is still to be defined.

***Z* enolates.** The analogous syn aldol reactions of (*S*)-16 via the *Z* enol borinate with achiral boron reagents, however, are non-selective [ref. 9a]. Here reagent control from the two enantiomeric  $\text{lpc}_2\text{BOTf}$  reagents can be used effectively, as in **22**  $\rightarrow$  **23** (SA) and **24**  $\rightarrow$  **25** (SS). For the syn-syn isomer, a substrate-controlled aldol reaction via Sn(II) enolate **26** is more convenient [ref. 11]. Internal chelation by the benzyl ether in the aldol *TS-VI* presumably leads to high levels of enolate  $\pi$ -face differentiation (not possible for boron).

#### ALDOL-3: Diastereoselective aldol reactions of $\alpha$ , $\beta$ -chiral ethyl ketones (6 $\rightarrow$ 8 in Scheme 1)


We have also explored the stereocontrol resulting from a second aldol reaction using the syn and anti ethyl ketones formed in **Scheme 3**. In the case of (*S,S*)-**27** and (*S,R*)-**28** (or their enantiomers), prepared by aldol reactions of diethylketone with methacrolein and hydroxyl protection ( $P = \text{SiMe}_2^t\text{Bu}$ ,  $\text{Si}^i\text{Pr}_3$  or PMB), these now function as tripropionate equivalents. The aldol products can be further elaborated, as shown in **Scheme 5**, by ketone reduction, **29**  $\rightarrow$  **30**, alkene hydroboration, **30**  $\rightarrow$  **31**, etc. Only about half the stereoisomers are readily accessible, making this strategy less general than that based on the  $\alpha$ -chiral ethyl ketones (*R*)- and (*S*)-**16**.

***E* enolates.** Enolisation by dicyclohexylboron chloride and  $\text{Et}_3\text{N}$  gives the *E* enolates, **27**  $\rightarrow$  **33** and **28**  $\rightarrow$  **35**, which now attack the si-face of an aldehyde like methacrolein to give mainly the anti-syn adducts **34** and **36** (**Scheme 7**) [ref. 12a,b]. Similar stereochemical results have been reported by Evans for related *E* enol borinates [ref. 12c]. We believe that the aldol addition is now proceeding preferentially through *TS-VII*, which minimises A(1,3) allylic strain with the *E* enol methyl group and directs the large  $R_L$  group away from the pseudoaxial ligand on boron. Note that the enolate  $\pi$ -face selectivity has now reversed compared to that observed for **20**, which lacks the alkyl  $\beta$ -substituent and gives only reaction on the aldehyde re-face. When  $R_L$  is benzyloxymethyl, re-face attack evidently wins out due to electronic effects, as in **20**  $\rightarrow$  **21** (**Scheme 6**). However, the steric effect from a large  $R_L$  group now overcomes any electronic preference from the ether oxygen orientation.


***Z* enolates.** Enolisation by 9-BBNOTf or  $^t\text{Bu}_2\text{BOTf}$  and  $^i\text{Pr}_2\text{NEt}$  gives the *Z* enolates, **27**  $\rightarrow$  **37** and **28**  $\rightarrow$  **39**, which undergo aldol addition to the re-face of an aldehyde like methacrolein with high diastereoselectivity (**Scheme 7**)

[ref. 12b, 13]. The syn-syn adducts **38** and **40** are typically obtained with around 95% ds. The preferred transition structure is now *TS-VIII*, which is supported by our force-field analysis [ref. 3]. Note that high levels of substrate control in the *Z* enol borinates with a large  $R_L$  group can now be obtained, irrespective of its relative configuration, while it is greatly reduced when  $R_L$  is relatively small like benzyloxymethyl (cf. **16**).


Scheme 6



Scheme 7





This process can be combined with a kinetic resolution (**Scheme 8**), by using the racemic ketone **27** with (+)-*lpc*<sub>2</sub>BOTf (*ent*-**9**) enolisation to give a fast-reacting (matched) and slow-reacting (mismatched) *Z* enol borinate [ref. 13b]. Aldol reaction with 0.5 equivalent of methacrolein then gives the syn-syn aldol adduct **41** with high ds and ee, while the mismatched enolate is returned as enantiomerically enriched starting ketone. We have used **41** in an asymmetric synthesis of the ansa chain segment **42** of rifamycin S (*via* **29** → **30** → **32** in **Scheme 5**), illustrating the use of **27** as a tripropionate reagent.

**Scheme 8****KINETIC RESOLUTION****APPLICATIONS TO THE SYNTHESIS OF POLYPROPIONATE NATURAL PRODUCTS**

This methodology has been extensively applied in our group to the total synthesis of a wide range of naturally-occurring polypropionates. Examples include:

- **ALDOL-1 /3 analysis:** oleandomycin [ref. 13a], ebelactone A [ref. 17], rifamycin S [ref. 13b].
  - **ALDOL-2 analysis:** oleandomycin [ref. 14], denticulatin A and B [ref. 15a], muamvatin [ref. 15b], swinholide A [ref. 16], tirandamycin A [ref. 9c], etheromycin [ref. 18], siphonarins B [ref. 19], scytophycin C [ref. 20].
- A selection of these are briefly outlined here.

**Scheme 9****Scheme 10**

### Oleandolide





The boron-mediated aldol reactions of ethyl ketones with aldehydes were initially investigated in the context of a synthesis of the 14-membered macrolide, oleandolide (oleandomycin aglycone). Our first approach to its secoacid **1** was based on the *ALDOL-1* /3 analysis of **Scheme 1** [ref. 13a, 14b]. Here the synthesis of a suitable C<sub>8</sub>–C<sub>13</sub> segment relied on sequential aldol reactions of diethylketone with acetaldehyde and crotonaldehyde (**Scheme 9**). This failed to deliver the desired syn-anti stereoisomer via the *Z* enol borinate from **43** (9-BBNOTf, <sup>t</sup>Pr<sub>2</sub>NEt), giving instead **44** (see **Scheme 7** for explanation). Use of the chiral reagent **9** reduces the stereoselectivity somewhat (SS : SA ca 3:1), but in this mismatched situation it cannot reverse the dominating substrate preference for the SS isomer [ref. 13a]. Changing the enolate stereochemistry from *Z* to *E* (Hex<sub>2</sub>BCl, Et<sub>3</sub>N) again failed to give the necessary anti relationship between the methyl groups at C<sub>10</sub> and C<sub>12</sub>. Now the enolate reacted on its other face to give **45** (see **Scheme 7** again)!

These stereochemical problems were finally solved by adopting the alternative *ALDOL-2* analysis (**Scheme 10**). Using the more versatile dipropionate reagent (*S*)-**16** and the aldol chemistry described in **Scheme 6**, syntheses of two different C<sub>8</sub>–C<sub>13</sub> segments, **46** → **47** and **48** → **49**, together with a C<sub>1</sub>–C<sub>7</sub> segment, **50** → **51**, were readily achieved. This has now evolved into two competing syntheses of oleandolide. The first is based on reagent-control in the aldol steps leading to the (9*S*)-macrolide **52** [ref 14a], while the second is based on substrate-control giving the (9*R*)-macrolide **53** [ref. 14b].

### Denticulatin A and B

The enantiomeric dipropionate reagent (*R*)-**16** has been employed in the first stereocontrolled synthesis of (-)-denticulatin B [ref. 15a]. This is a member of an intriguing class of polypropionates isolated from Siphonariid pulmonate molluscs (false limpets) [ref. 21]. In our denticulatin synthesis (**Scheme 11**), the C<sub>3</sub>–C<sub>10</sub> segment **54** was readily assembled with 96% ds by a substrate-controlled anti-anti boron aldol reaction and an *in situ* reduction of the aldolate by LiBH<sub>4</sub>. This was then elaborated at both ends to give the ethyl ketone **55**, which was submitted to an Evans Ti(IV) syn-syn aldol reaction [ref. 22] (see similar reaction for boron in **Scheme 7** via *TS-VII*) with a chiral aldehyde.

**Scheme 11**




The major aldol adduct **56** was first oxidised to give **57** then deprotected to give exclusively (-)-denticulatin B, retaining the C<sub>10</sub> configuration. Epimerisation of **57** at C<sub>10</sub> occurs on silica gel, leading to (-)-denticulatin A. Related chemistry is being applied to the synthesis of other Siphonariid metabolites, including siphonaridin B [ref. 23] and muamvatin (stereochemistry yet to be fully assigned) [ref. 24].


### Swinholide A

Swinholide A, a novel cytotoxic macrolide from the marine sponge *Theonella swinhoei*, has an unusual 44-membered dilactone ring [ref. 25]. Boron aldol reactions, under both substrate and reagent control, feature in our planned synthesis of its secoacid **2** (Scheme 12) [ref. 16]. The dipropionate reagent (*S*)-**16** was first combined, via its *E* dicyclohexylenol borinate, with the aldehyde **58** to give the anti-anti adduct **59** with  $\geq 97\%$  ds. This was further elaborated by stereocontrolled ketone reduction and alkene hydroboration to give the C<sub>19</sub>–C<sub>32</sub> segment **60**. Reagent-controlled aldol coupling between the ethyl ketone **61**, via the *Z* enol borinate **62**, and the aldehyde **63** (triple asymmetric induction) should allow the stereocontrolled assembly of the secoacid precursor **64**.

Scheme 12



Scheme 13






**Ebelactone A**

The *ALDOL-1/3* analysis in **Scheme 1** was successfully applied to the first synthesis of the  $\beta$ -lactone enzyme inhibitor, ebelactone A [ref. 17, 26]. As shown in **Scheme 13**, diethylketone was sequentially aldol coupled with 2-ethylacrolein to give **65**, then with methacrolein to give the syn-syn adduct **66**. The ketone group at C<sub>9</sub> can then be carried through the remainder of the synthesis without protection. An Ireland-Claisen rearrangement, **67** → **68**, followed by a propionate aldol reaction to give **69**,  $\beta$ -lactone formation, and hydrogenation at C<sub>12</sub> gave ebelactone A.

As an extension of this work, the combination of sequential diethylketone aldol reactions and double Ireland-Claisen rearrangements was applied to two-directional polypropionate synthesis, as in **70** → **71** and **72** → **73** in **Scheme 14** [ref. 12a]. Note again that the ketone carbonyl group can be successfully carried through these transformations without protection.

**Scheme 14**

**Acknowledgements** It is a pleasure to thank my able and enthusiastic co-workers at Cambridge, whose work is described in this article and who are cited by name in the accompanying references. We gratefully acknowledge support from the SERC, the EC, the ACS-PRF, and the following companies: Lilly Research, ICI Pharmaceuticals, Roussel Laboratories, and Rhone-Poulenc-Rorer. Professor C. Gennari and his group at Milan are thanked for their contributions to some of this work through a collaboration supported by the EC and NATO.

**REFERENCES**

- [1] Reviews: (a) I. Paterson and M. M. Mansuri, *Tetrahedron* **41**, 3569 (1985); (b) S. Masamune and P. A. McCarthy, *Macrolide Antibiotics. Chemistry, Biology, and Practice*, S. Omura, Ed., Academic Press, Orlando (1984); (c) R. W. Hoffmann, *Angew. Chem., Int. Ed. Engl.* **26**, 489 (1987).
- [2] Review: M. Kim, S. F. Williams and S. Masamune, *Comprehensive Organic Synthesis* **2**, p. 239, B. M. Trost and I. Fleming, Ed., Pergamon Press, Oxford (1991).
- [3] (a) A. Bernardi, A. M. Capelli, C. Gennari, J. M. Goodman and I. Paterson, *J. Org. Chem.* **55**, 3576 (1990); (b) A. Bernardi, A. M. Capelli, A. Comotti, C. Gennari, M. Gardner, J. M. Goodman and I. Paterson, *Tetrahedron* **47**, 3471 (1991).
- [4] (a) I. Paterson, J. M. Goodman, M. A. Lister, R. C. Schumann, C. K. McClure and R. D. Norcross, *Tetrahedron* **46**, 4663 (1990); (b) I. Paterson, M. A. Lister and C. K. McClure, *Tetrahedron Lett.* **27**, 4787 (1986); (c) I. Paterson and J. M. Goodman, *Tetrahedron Lett.* **30**, 997 (1989).
- [5] D. A. Evans, J. V. Nelson, E. Vogel and T. R. Taber, *J. Amer. Chem. Soc.* **103**, 3099 (1981).
- [6] H. C. Brown, R. K. Dhar, R. K. Bakshi, P. K. Pandiarajan and B. Singaram, *J. Am. Chem. Soc.* **111**, 3441 (1989).
- [7] J. M. Goodman, unpublished results.

- [8] C. Gennari, C. T. Hewkin, F. Molinari, A. Bernardi, A. Comotti, J. M. Goodman and I. Paterson, J. Org. Chem. in press.
- [9] (a) I. Paterson and M. A. Lister, Tetrahedron Lett. **29**, 585 (1988); (b) I. Paterson, J. M. Goodman and M. Isaka, Tetrahedron Lett. **30**, 7121 (1989); (c) I. Paterson, M. A. Lister and G. R. Ryan, Tetrahedron Lett. **32**, 1749 (1991); (d) For an alternative class of dipropionate reagent, see: D. A. Evans, J. S. Clark, R. Metternich, V. J. Novack and G. S. Sheppard, J. Am. Chem. Soc. **112**, 866 (1990).
- [10] I. Paterson and J. A. Channon, Tetrahedron Lett. **33**, 797 (1992).
- [11] I. Paterson and R. D. Tillyer, Tetrahedron Lett. in press.
- [12] (a) I. Paterson, A. N. Hulme and D. J. Wallace, Tetrahedron Lett. **32**, 7601 (1991); (b) I. Paterson, R. D. Norcross, A. N. Hulme and M. Gardner, unpublished results; (c) D. A. Evans, H. P. Ng, J. S. Clark and D. L. Rieger, Tetrahedron **48**, 2127 (1992).
- [13] (a) I. Paterson and C. K. McClure, Tetrahedron Lett. **28**, 1229 (1987); (b) I. Paterson, C. K. McClure and R. C. Schumann, Tetrahedron Lett. **30**, 1293 (1989); (c) Similar stereochemical results are obtained using titanium enolates, see: D. A. Evans, D. L. Rieger, M. T. Bilodeau and F. Urpi J. Am. Chem. Soc. **113**, 1047 (1991).
- [14] (a) I. Paterson, M. A. Lister and R. D. Norcross, Tetrahedron Lett. **33**, 1767 (1992); (b) I. Paterson, R. D. Norcross and P. Romeo, unpublished results.
- [15] (a) I. Paterson and M. V. Perkins, Tetrahedron Lett. **33**, 801 (1992); (b) I. Paterson and M. V. Perkins, unpublished results.
- [16] (a) I. Paterson and J. G. Cumming, Tetrahedron Lett. **33**, 2847 (1992); (b) I. Paterson and J. D. Smith, J. Org. Chem. **57**, 3261 (1992); (c) I. Paterson, J. G. Cumming, J. D. Smith and R. Ward, unpublished results.
- [17] (a) I. Paterson and A. N. Hulme, Tetrahedron Lett. **31**, 7513 (1990); (b) I. Paterson and A. N. Hulme, unpublished results.
- [18] I. Paterson and R. D. Tillyer, unpublished results.
- [19] I. Paterson, J. A. Channon and A. Franklin, unpublished results.
- [20] I. Paterson and K.-S. Yeung, unpublished results.
- [21] J. E. Hochlowski, D. J. Faulkner, G. K. Matsumoto and J. Clardy, J. Am. Chem. Soc. **105**, 7413 (1983).
- [22] D. A. Evans, J. S. Clark, R. Metternich, V. J. Novack and G. S. Sheppard, J. Am. Chem. Soc. **112**, 866 (1990).
- [23] J. E. Hochlowski, J. C. Coll, D. J. Faulkner, J. E. Biskupiak, C. M. Ireland, Z. Qi-tai, H. Cun-heng and J. Clardy, J. Am. Chem. Soc. **106**, 6748 (1984).
- [24] D. M. Roll, J. E. Biskupiak, C. L. Mayne and C. M. Ireland, J. Am. Chem. Soc. **108**, 6680 (1986).
- [25] (a) I. Kitagawa, M. Kobayashi, T. Katori and M. Yamashita, J. Am. Chem. Soc. **112**, 3710 (1990); (b) S. Carmely and Y. Kashman, Tetrahedron Lett. **26**, 511 (1985).
- [26] (a) H. Umezawa, A. Takaaki, K. Uotani, M. Hamada, T. Takeuchi and S. Takahashi, J. Antibiotics **33**, 1594 (1980); (b) K. Uotani, H. Naganawa, S. Kondo, T. Aoyagi and H. Umezawa, J. Antibiotics **35**, 1495 (1982).